Friday, February 10, 2012 Issue 6   VOLUME 1 ISSUE 6   TOPICS Parkinson's disease Dystonia ARCHIVE Issue 5 June 21, 2004 Vol. 1 Issue 5 [MORE] SEARCH Search for articles containing: SUBSCRIBE Subscribe to WE MOVE News The Long-term Treatment of Focal Hand Dystonia with Botulinum Toxin Injections Researchers investigated the outcome of more than 1,100 botulinum toxin injection sessions in 164 patients with focal hand dystonia who were treated at the National Institutes of Health. The researchers found that 61% of the injection sessions provided at least minimal improvement in focal hand dystonia. The primary reasons that patients stopped the treatments were a lack of response, the inconvenience of traveling to the medical center, and lack of continuity in care. [FULL STORY]   The Use of Botulinum Toxin for the Treatment of Focal Hand Dystonia in Musicians A retrospective study in musicians with focal hand dystonia showed that botulinum toxin A (Botox®) injection therapy was effective in treating focal hand dystonia in 64% of musicians, independent of the type of instrument played. [FULL STORY]   Phase 2 Study of GDNF Fails to Reach End Points Amgen recently announced that the findings of a double-blind placebo-controlled study of glial cell line-derived neurotrophic factor (GDNF) for the treatment of Parkinson’s disease do not support the previously published positive results from a small open-label trial. [FULL STORY]   Pediatric Treatment Center Database Available from WE MOVE WE MOVE’s Treatment Center Database provides a valuable resource to parents of children with movement disorders. [FULL STORY]     Supported by an educational grant from the Medtronic Foundation Published by WE MOVE Copyright © 2004 WE MOVE. All rights reserved. TELL A FRIEND   Judith Blazer, Executive Director, WE MOVE    Edited by Richard Robinson, Cate Murray and Joy Leffler

Powered by IMN™